

Supplementary Table 1. SARS-CoV-2 monoclonal antibodies authorized for COVID-19 treatment in children and adolescents⁴⁸⁾

	Bamlanivimab/etesevimab	Casirivimab/imdevimab	Sotrovimab
Minimum age and weight	>1 kg Available for infants and young children <12 years	≥12 years and >40 kg	≥12 years and >40 kg
Dosage	1 to 12 kg: 12 mg/kg and 24 mg/kg >12 to 20 kg: 175 mg/350 mg >20 to 40 kg: 350 mg/700 mg ≥40 kg: 700 mg/1,400 mg	600 mg/600 mg	500 mg
Route of administration	IV	IV preferred; SC alternative if IV not feasible or available	IV
Timing of administration	Provide ASAP after positive SARS-CoV-2 test and within 10 days of symptom onset		
EUA criteria	Nonhospitalized patient, and Laboratory-confirmed SARS-CoV-2 infection, and Mild to moderate COVID-19, and Within 10 days of symptom onset, and High risk for progressing to severe COVID-19 and/or hospitalization		
High-risk criteria	Body mass index ≥ 85th percentile for age and gender Immunosuppressive disease or receipt of immunosuppressive therapies Neurodevelopmental disorders (e.g., cerebral palsy, trisomy 21) A medical-related technological dependence that is not related to COVID-19 (e.g., tracheostomy, positive pressure ventilation, gastrostomy) Sickle cell disease Congenital or acquired heart disease Chronic lung disease (e.g., interstitial lung disease, tuberculosis); asthma or other chronic respiratory disease that requires daily medication for control Diabetes Chronic kidney disease Chronic liver disease (e.g., cirrhosis, autoimmune hepatitis) Pregnancy; or Age <1 year		

SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; COVID-19, coronavirus disease 2019; IV, intravenous; SC, subcutaneous; ASAP, as soon as possible; EUA, emergency use approval.